Oxeia Biopharmaceuticals is a clinical stage biotech company developing drug treatments for concussion and underlying neuro-metabolic dysfunction.

According to the Centers for Disease Control, 2.2 million cases of mild traumatic brain injury (concussions) are seen in US hospital emergency rooms every year. Other estimates suggest 4 – 5 million concussions to be more accurate if unreported events are also considered. Research in the last two decades has increasingly linked concussions to neurodegenerative conditions including dementia, Alzheimer’s disease, and chronic traumatic encephalopathy (CTE).

The gravity of a concussion is now paramount and the notion of ‘getting your bell rung’ is no longer a passing consequence of contact sports or military activity. It is a significant unmet medical need that may lead to more debilitating neurological disease. Individuals at risk for concussions need innovative medical solutions to aid recovery – Rest is not enough.